Anthera Pharmaceuticals Inc (ANTH PINK) stock market data APIs
$0.0001
0(0%)
as of March 21, 2025
Anthera Pharmaceuticals Inc Financial Data Overview
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Prev. Close
0.0001
Open
0.0001
High
0.0001
Low
0.0001
52 wk Range
0.0001-0.0002
Market Cap
618 K
Shares Outstanding
26 179 K
EPS
0
Beta
-73.984
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Anthera Pharmaceuticals Inc data using free add-ons & libraries
Get Anthera Pharmaceuticals Inc Fundamental Data
Anthera Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -36 402 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-05-09
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Anthera Pharmaceuticals Inc News
New
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets
HAYWARD, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing t...
Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight Medical Products, Eclipse Resources, and Aircastle with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders,...
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”)Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”)Further devel...
Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference
HAYWARD, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and l...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
